Cargando…

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma

BACKGROUND: Neuroblastoma (NB) patients with MYCN amplification or overexpression respond poorly to current therapies and exhibit extremely poor clinical outcomes. PI3K-mTOR signaling-driven deregulation of protein synthesis is very common in NB and various other cancers that promote MYCN stabilizat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kling, Matthew J., Griggs, Connor N., McIntyre, Erin M., Alexander, Gracey, Ray, Sutapa, Challagundla, Kishore B., Joshi, Shantaram S., Coulter, Don W., Chaturvedi, Nagendra K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474810/ https://www.ncbi.nlm.nih.gov/pubmed/34565342 http://dx.doi.org/10.1186/s12885-021-08782-9

Ejemplares similares

A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma
por: Kling, Matthew J., et al.
Publicado: (2022)

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy
por: Chaturvedi, Nagendra K., et al.
Publicado: (2018)

Improved therapy for neuroblastoma using a combination approach: superior efficacy with vismodegib and topotecan
por: Chaturvedi, Nagendra K., et al.
Publicado: (2016)

Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513
por: Coulter, Don W., et al.
Publicado: (2016)

Amino Acids Regulate Cisplatin Insensitivity in Neuroblastoma
por: Gunda, Venugopal, et al.
Publicado: (2020)

Effects of novel pyrrolomycin MP1 in MYCN amplified chemoresistant neuroblastoma cell lines alone and combined with temsirolimus
por: McGuire, Timothy R., et al.
Publicado: (2019)

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma
por: Lampis, Silvia, et al.
Publicado: (2022)

miR‐15a‐5p, miR‐15b‐5p, and miR‐16‐5p inhibit tumor progression by directly targeting MYCN in neuroblastoma
por: Chava, Srinivas, et al.
Publicado: (2019)

Exosomes secreted under hypoxia enhance stemness in Ewing’s sarcoma through miR-210 delivery
por: Kling, Matthew J., et al.
Publicado: (2020)

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors
por: Vaughan, Lynsey, et al.
Publicado: (2016)

Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma
por: Chaturvedi, Nagendra K., et al.
Publicado: (2019)

Long non-coding RNA profiling of pediatric Medulloblastoma
por: Kesherwani, Varun, et al.
Publicado: (2020)

miR-15a and miR-15b modulate natural killer and CD8(+)T-cell activation and anti-tumor immune response by targeting PD-L1 in neuroblastoma
por: Pathania, Anup S., et al.
Publicado: (2022)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma()
por: Felgenhauer, Joshua, et al.
Publicado: (2018)

Ferroptosis vulnerability in MYCN‐driven neuroblastomas
por: Dasgupta, Shayani, et al.
Publicado: (2022)

MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
por: Pouliou, Marialena, et al.
Publicado: (2023)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2014)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Therapeutic potential of targeting MYCN: A case series report of neuroblastoma with MYCN amplification
por: Huang, Can, et al.
Publicado: (2020)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

Regulation of MYCN expression in human neuroblastoma cells
por: Jacobs, Joannes FM, et al.
Publicado: (2009)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

MYCN amplification and ATRX mutations are incompatible in neuroblastoma
por: Zeineldin, Maged, et al.
Publicado: (2020)

MYCN in Neuroblastoma: “Old Wine into New Wineskins”
por: Braoudaki, Maria, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
por: Nunes, Carolina, et al.
Publicado: (2022)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2016)

On the significance of germline cytogenetic rearrangements at MYCN locus in neuroblastoma
por: Lipska, Beata S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1hde3suv41rmgvuu00iit4rlb8